DE69307340D1 - Chinuclidin derivat als substanz p antagonist - Google Patents

Chinuclidin derivat als substanz p antagonist

Info

Publication number: DE69307340D1
Authority: DE; Germany
Prior art keywords: pct; substance; derivative; chinuclidine; antagonist
Prior art date: 1992-11-12
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

DE69307340T

Other languages

English (en)

Other versions

DE69307340T2 (de

Inventor

Fumitaka Ito

Hiroshi Kondo

Masami Nakane

Kaoru Shimada

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Pfizer Inc

Original Assignee

Pfizer Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-11-12

Filing date

1993-07-19

Publication date

1997-02-20

1993-07-19 Application filed by Pfizer Inc filed Critical Pfizer Inc

1997-02-20 Application granted granted Critical

1997-02-20 Publication of DE69307340D1 publication Critical patent/DE69307340D1/de

1997-04-24 Publication of DE69307340T2 publication Critical patent/DE69307340T2/de

2013-07-20 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, ***e
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

DE69307340T 1992-11-12 1993-07-19 Chinuclidin derivat als substanz p antagonist Expired - Fee Related DE69307340T2 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US97524492A	1992-11-12	1992-11-12
PCT/US1993/006624 WO1994011368A1 (en)	1992-11-12	1993-07-19	Quinuclidine derivative as substance p antagonist

Publications (2)

Publication Number	Publication Date
DE69307340D1 true DE69307340D1 (de)	1997-02-20
DE69307340T2 DE69307340T2 (de)	1997-04-24

Family

ID=25522825

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DE69307340T Expired - Fee Related DE69307340T2 (de)	1992-11-12	1993-07-19	Chinuclidin derivat als substanz p antagonist

Country Status (19)

Country	Link
US (1)	US5886009A (de)
EP (1)	EP0668863B1 (de)
JP (1)	JP2668164B2 (de)
KR (1)	KR950704311A (de)
CN (1)	CN1034732C (de)
AT (1)	ATE147385T1 (de)
AU (1)	AU676489B2 (de)
CA (1)	CA2149242C (de)
DE (1)	DE69307340T2 (de)
DK (1)	DK0668863T3 (de)
ES (1)	ES2096312T3 (de)
FI (1)	FI934983A (de)
GR (1)	GR3022459T3 (de)
IL (1)	IL107495A (de)
MX (1)	MX9307062A (de)
MY (1)	MY130145A (de)
NZ (1)	NZ254604A (de)
WO (1)	WO1994011368A1 (de)
ZA (1)	ZA938421B (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6387925B1 (en) *	1999-06-01	2002-05-14	Pfizer Inc.	Polymorphs of a crystalline azo-bicyclo (2.2.2) oct-3-yl amine citrate and their pharmaceutical compositions
US6262067B1 (en) *	1999-06-22	2001-07-17	Pfizer Inc.	Polymorphs of a crystalline azo-bicyclo 2,2,2 OCT-3-yl amine dihydrochloride and their pharmaceutical compositions
DE10001785A1 (de) *	2000-01-18	2001-07-19	Boehringer Ingelheim Pharma	NK¶1¶-Rezeptor-Antagonisten zur Behandlung des Restless Legs Syndroms
US6861526B2 (en) *	2002-10-16	2005-03-01	Pfizer Inc.	Process for the preparation of (S,S)-cis-2-benzhydryl-3-benzylaminoquinuclidine
WO2005051919A1 (en) *	2003-11-26	2005-06-09	Pfizer Products Inc.	Aminopyrazole derivatives as gsk-3 inhibitors
HUE034099T2 (en) *	2004-01-30	2018-01-29	Zoetis Services Llc	Antimicrobial preservatives for the delivery of multidose formulations using beta-cyclodextrins for liquid dosage forms
MX2007000428A (es)	2004-07-15	2008-03-05	Amr Technology Inc	Tetrahidroisoquinolinas sustituidas con arilo y heteroarilo y uso de las mismas para bloquear la captacion de norepinefrina, dopamina y serotonina.
ATE550019T1 (de)	2005-05-17	2012-04-15	Merck Sharp & Dohme	Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs
CA2615403C (en)	2005-07-15	2015-06-16	Amr Technology, Inc.	Aryl-and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
AU2006297443B2 (en)	2005-09-29	2010-08-12	Merck Sharp & Dohme Corp.	Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
GB0603041D0 (en)	2006-02-15	2006-03-29	Angeletti P Ist Richerche Bio	Therapeutic compounds
CA2664113C (en)	2006-09-22	2013-05-28	Merck & Co., Inc.	Use of platencin and platensimycin as fatty acid synthesis inhibitors to treat obesity, diabetes and cancer
US20110218176A1 (en)	2006-11-01	2011-09-08	Barbara Brooke Jennings-Spring	Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
CN101190330A (zh)	2006-11-30	2008-06-04	深圳市鼎兴生物医药技术开发有限公司	胆碱酯酶在拮抗速激肽药物中的应用
EP2109608B1 (de)	2007-01-10	2011-03-23	Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A.	Amidsubstituierte indazole als poly-(adp-ribose)-polymerase (parp)-hemmer
US8106086B2 (en)	2007-04-02	2012-01-31	Msd K.K.	Indoledione derivative
JP5501227B2 (ja)	2007-06-27	2014-05-21	メルク・シャープ・アンド・ドーム・コーポレーション	ヒストンデアセチラーゼ阻害剤としての４−カルボキシベンジルアミノ誘導体
AU2009222122A1 (en)	2008-03-03	2009-09-11	Tiger Pharmatech	Tyrosine kinase inhibitors
US9156812B2 (en)	2008-06-04	2015-10-13	Bristol-Myers Squibb Company	Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
EP2413932A4 (de)	2009-04-01	2012-09-19	Merck Sharp & Dohme	Hemmer der akt-aktivität
ES2662072T3 (es)	2009-05-12	2018-04-05	Albany Molecular Research, Inc.	7-([1,2,4]triazolo[1,5-a]piridin-6-il)-4-(3,4-diclorofenil)-1,2,3,4-tetrahidroisoquinolina y uso de la misma
KR20120034644A (ko)	2009-05-12	2012-04-12	알바니 몰레큘라 리써치, 인크.	아릴, 헤테로아릴, 및 헤테로사이클 치환된 테트라하이드로이소퀴놀린 및 이의 용도
EP2429293B1 (de)	2009-05-12	2014-10-29	Bristol-Myers Squibb Company	KRISTALLINE FORMEN VON (S)-7-([1,2,4]TRIAZOL[1,5-a]PYRIDIN-6-YL)-4-(3,4-DICHLORPHENYL)-1,2,3,4-TETRAHYDROISOCHINOLIN UND IHRE VERWENDUNG
KR101485645B1 (ko)	2009-10-14	2015-01-22	머크 샤프 앤드 돔 코포레이션	ｐ53 활성을 증가시키는 치환된 피페리딘 및 그의 용도
WO2011163330A1 (en)	2010-06-24	2011-12-29	Merck Sharp & Dohme Corp.	Novel heterocyclic compounds as erk inhibitors
CN107090456B (zh)	2010-08-02	2022-01-18	瑟纳治疗公司	使用短干扰核酸的RNA干扰介导的联蛋白（钙粘蛋白关联蛋白质），β1基因表达的抑制
HUE044815T2 (hu)	2010-08-17	2019-11-28	Sirna Therapeutics Inc	Hepatitisz B vírus (HBV) génexpressziójának RNS-interferencia közvetített gátlása, rövid interferáló nukleinsav (SINS) alkalmazásával
US8883801B2 (en)	2010-08-23	2014-11-11	Merck Sharp & Dohme Corp.	Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
WO2012030685A2 (en)	2010-09-01	2012-03-08	Schering Corporation	Indazole derivatives useful as erk inhibitors
US9242981B2 (en)	2010-09-16	2016-01-26	Merck Sharp & Dohme Corp.	Fused pyrazole derivatives as novel ERK inhibitors
WO2012058210A1 (en)	2010-10-29	2012-05-03	Merck Sharp & Dohme Corp.	RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
US9351965B2 (en)	2010-12-21	2016-05-31	Merck Sharp & Dohme Corp.	Indazole derivatives useful as ERK inhibitors
CN103732592A (zh)	2011-04-21	2014-04-16	默沙东公司	***-1受体抑制剂
US9023865B2 (en)	2011-10-27	2015-05-05	Merck Sharp & Dohme Corp.	Compounds that are ERK inhibitors
EP3919620A1 (de)	2012-05-02	2021-12-08	Sirna Therapeutics, Inc.	Zusammensetzungen mit kurzer interferierender nukleinsäure (sina)
CA2882950A1 (en)	2012-09-28	2014-04-03	Merck Sharp & Dohme Corp.	Novel compounds that are erk inhibitors
EP2919788A4 (de)	2012-11-14	2016-05-25	Univ Johns Hopkins	Verfahren und zusammensetzungen zur behandlung von schizophrenie
LT2925888T (lt)	2012-11-28	2018-01-10	Merck Sharp & Dohme Corp.	Vėžio gydymo kompozicijos ir būdai
BR112015013611A2 (pt)	2012-12-20	2017-11-14	Merck Sharp & Dohme	composto, e, composição farmacêutica
WO2014120748A1 (en)	2013-01-30	2014-08-07	Merck Sharp & Dohme Corp.	2,6,7,8 substituted purines as hdm2 inhibitors
US20160194368A1 (en)	2013-09-03	2016-07-07	Moderna Therapeutics, Inc.	Circular polynucleotides
US10947234B2 (en)	2017-11-08	2021-03-16	Merck Sharp & Dohme Corp.	PRMT5 inhibitors
US20210309688A1 (en)	2018-08-07	2021-10-07	Merck Sharp & Dohme Corp.	Prmt5 inhibitors
US20210277009A1 (en)	2018-08-07	2021-09-09	Merck Sharp & Dohme Corp.	Prmt5 inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MX18467A (es) *	1988-11-23	1993-07-01	Pfizer	Agentes terapeuticos de quinuclidinas
DK0532527T3 (da) *	1990-06-01	1995-01-02	Pfizer	3-amino-2-arylquinuclidiner, fremgangsmåde til fremstilling deraf og farmaceutiske præparater indeholdende disse
DE9290063U1 (de) *	1991-05-31	1994-02-24	Pfizer	Chinuclidin-Derivate
EP0533280B2 (de) *	1991-09-20	2004-12-01	Glaxo Group Limited	Neue medizinische Indikation für Tachykinin-Antagonisten
US5340826A (en) *	1993-02-04	1994-08-23	Pfizer Inc.	Pharmaceutical agents for treatment of urinary incontinence

1993
- 1993-07-19 NZ NZ254604A patent/NZ254604A/en unknown
- 1993-07-19 DE DE69307340T patent/DE69307340T2/de not_active Expired - Fee Related
- 1993-07-19 AT AT93917176T patent/ATE147385T1/de not_active IP Right Cessation
- 1993-07-19 EP EP93917176A patent/EP0668863B1/de not_active Expired - Lifetime
- 1993-07-19 KR KR1019950701877A patent/KR950704311A/ko not_active Application Discontinuation
- 1993-07-19 AU AU46780/93A patent/AU676489B2/en not_active Ceased
- 1993-07-19 WO PCT/US1993/006624 patent/WO1994011368A1/en active IP Right Grant
- 1993-07-19 ES ES93917176T patent/ES2096312T3/es not_active Expired - Lifetime
- 1993-07-19 US US08/500,958 patent/US5886009A/en not_active Expired - Fee Related
- 1993-07-19 CA CA002149242A patent/CA2149242C/en not_active Expired - Fee Related
- 1993-07-19 JP JP6502707A patent/JP2668164B2/ja not_active Expired - Lifetime
- 1993-07-19 DK DK93917176.5T patent/DK0668863T3/da active
- 1993-11-04 IL IL10749593A patent/IL107495A/en not_active IP Right Cessation
- 1993-11-09 MY MYPI93002345A patent/MY130145A/en unknown
- 1993-11-11 ZA ZA938421A patent/ZA938421B/xx unknown
- 1993-11-11 FI FI934983A patent/FI934983A/fi unknown
- 1993-11-11 MX MX9307062A patent/MX9307062A/es not_active IP Right Cessation
- 1993-11-11 CN CN93114371A patent/CN1034732C/zh not_active Expired - Fee Related
1997
- 1997-01-31 GR GR970400170T patent/GR3022459T3/el unknown

Also Published As

Publication number	Publication date
ATE147385T1 (de)	1997-01-15
CN1034732C (zh)	1997-04-30
CN1091134A (zh)	1994-08-24
EP0668863A1 (de)	1995-08-30
CA2149242C (en)	1998-08-04
IL107495A0 (en)	1994-02-27
WO1994011368A1 (en)	1994-05-26
NZ254604A (en)	1997-06-24
JP2668164B2 (ja)	1997-10-27
DE69307340T2 (de)	1997-04-24
IL107495A (en)	1998-12-27
CA2149242A1 (en)	1994-05-26
MY130145A (en)	2007-06-29
US5886009A (en)	1999-03-23
FI934983A (fi)	1994-05-13
AU676489B2 (en)	1997-03-13
MX9307062A (es)	1994-05-31
FI934983A0 (fi)	1993-11-11
JPH07508731A (ja)	1995-09-28
AU4678093A (en)	1994-06-08
EP0668863B1 (de)	1997-01-08
DK0668863T3 (da)	1997-06-30
GR3022459T3 (en)	1997-04-30
ES2096312T3 (es)	1997-03-01
ZA938421B (en)	1995-05-11
KR950704311A (ko)	1995-11-17

Legal Events

Date	Code	Title	Description
1998-02-12	8364	No opposition during term of opposition
2001-09-06	8339	Ceased/non-payment of the annual fee

Publication	Publication Date	Title
DE69307340D1 (de)	1997-02-20	Chinuclidin derivat als substanz p antagonist
FI935134A0 (fi)	1993-11-19	Substituerade 3-aminokinuklidiner
FI20000085A (fi)	2000-01-17	Menetelmä terapeuttisesti aktiivisten 4-amino-substituoitujen 2-azabicyklo/3.3.1/nonaanijohdannaisten valmistamiseksi
MY107157A (en)	1995-09-30	Quinuclidine derivatives.
UA27776C2 (uk)	2000-10-16	Похідні хінуклідину та їх фармацевтично прийнятні солі, що є антагоністами речовини р у ссавців, фармацевтична композиція, що має антагоністичну дію на речовину р у ссавців
MY116002A (en)	2003-10-31	Nk-1 receptor antagonists and 5ht3 receptor antagonists for the treatment of emesis
DK0738269T5 (da)	2000-12-18	Piperidinderivater med PAF-antagonistaktivitet
ATE269865T1 (de)	2004-07-15	Pyrazolo(3,4-g)chinoxaline als pdgf-rezeptor protein tyrosin-kinase inhibitoren
DK0823909T3 (da)	2003-01-20	Hidtil ukendte heterocykliske forbindelser
NO951865L (no)	1995-05-11	Quinuclidin-derivat som substans-P antagonist
DE69811487D1 (de)	2003-03-27	Benzoesäurederivate und deren medizinische verwendung